- Home
- RDHL vs BCDA Comparison
RDHL vs BCDA Comparison
Compare RDHL & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- BCDA
- Stock Information
- Founded
- RDHL 2009
- BCDA N/A
- Country
- RDHL Israel
- BCDA United States
- Employees
- RDHL N/A
- BCDA N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- BCDA Health Care
- Exchange
- RDHL Nasdaq
- BCDA Nasdaq
- Market Cap
- RDHL 4.3M
- BCDA 11.0M
- IPO Year
- RDHL N/A
- BCDA N/A
- Fundamental
- Price
- RDHL $2.02
- BCDA $2.12
- Analyst Decision
- RDHL
- BCDA Strong Buy
- Analyst Count
- RDHL 0
- BCDA 1
- Target Price
- RDHL N/A
- BCDA $25.00
- AVG Volume (30 Days)
- RDHL 19.3K
- BCDA 204.0K
- Earning Date
- RDHL 08-28-2025
- BCDA 08-12-2025
- Dividend Yield
- RDHL N/A
- BCDA N/A
- EPS Growth
- RDHL N/A
- BCDA N/A
- EPS
- RDHL N/A
- BCDA N/A
- Revenue
- RDHL $8,042,999.00
- BCDA $3,000.00
- Revenue This Year
- RDHL $381.91
- BCDA N/A
- Revenue Next Year
- RDHL N/A
- BCDA N/A
- P/E Ratio
- RDHL N/A
- BCDA N/A
- Revenue Growth
- RDHL 23.17
- BCDA N/A
- 52 Week Low
- RDHL $1.71
- BCDA $1.63
- 52 Week High
- RDHL $20.28
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- RDHL 57.04
- BCDA 44.60
- Support Level
- RDHL $1.75
- BCDA $1.98
- Resistance Level
- RDHL $2.08
- BCDA $2.45
- Average True Range (ATR)
- RDHL 0.10
- BCDA 0.16
- MACD
- RDHL 0.03
- BCDA -0.01
- Stochastic Oscillator
- RDHL 85.16
- BCDA 18.00
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).